D-3 Phosphoinositide Metabolism in Cells Treated with Platelet-derived Growth Factor
Overview
Authors
Affiliations
Despite extensive analysis of phosphoinositide 3-hydroxykinases (PI 3-kinases) at the molecular level, comparatively little is known about the mechanisms by which products of these enzymes exert their expected second-messenger functions. This study examines the metabolism of D-3 phosphoinositides in mouse Ph-N2 fibroblasts lacking the platelet-derived growth factor (PDGF) alpha-receptor. Treatment of these cultures with BB PDGF, but not AA PDGF, resulted in transient activation of PI 3-kinase activity measured in vitro. Treatment of myo-[3H]inositol-labelled Ph-N2 cells with BB PDGF resulted in the rapid induction of PtdIns(3,4)P2 and PtdIns(3,4,5)P3 and, to a smaller extent, PtdIns3P. The appearance of PtdIns(3,4,5)P3 preceded that of PtdIns(3,4)P2 and PtdIns3P after the addition of PDGF, suggesting that PtdIns(4,5)P2 is the preferred substrate of the agoniststimulated PI 3-kinase in intact cells. Treatment of both resting and PDGF-stimulated cells with the fungal metabolite wortmannin resulted in pronounced, selective effects on the levels of all D-3 phosphoinositides. Kinetic studies with this PI 3-kinase inhibitor revealed the presence of at least two independent routes for the biosynthesis of D-3 phosphoinositides in PDGF-treated cells.
The Importance of Being PI3K in the RAS Signaling Network.
Cuesta C, Arevalo-Alameda C, Castellano E Genes (Basel). 2021; 12(7).
PMID: 34356110 PMC: 8303222. DOI: 10.3390/genes12071094.
Simultaneous Detection of Phosphoinositide Lipids by Radioactive Metabolic Labeling.
Steinfeld N, Giridharan S, Kauffman E, Weisman L Methods Mol Biol. 2021; 2251:1-17.
PMID: 33481228 PMC: 8059495. DOI: 10.1007/978-1-0716-1142-5_1.
Ho C, Choy C, Botelho R J Vis Exp. 2016; (107).
PMID: 26780479 PMC: 4781033. DOI: 10.3791/53529.
Vaccari I, Dina G, Tronchere H, Kaufman E, Chicanne G, Cerri F PLoS Genet. 2011; 7(10):e1002319.
PMID: 22028665 PMC: 3197679. DOI: 10.1371/journal.pgen.1002319.
RAS Interaction with PI3K: More Than Just Another Effector Pathway.
Castellano E, Downward J Genes Cancer. 2011; 2(3):261-74.
PMID: 21779497 PMC: 3128635. DOI: 10.1177/1947601911408079.